DPP-4 inhibition with linagliptin ameliorates cognitive impairment and brain atrophy induced by transient cerebral ischemia in type 2 diabetic mice
Conclusions:
DPP-4 inhibition with linagliptin counteracted cognitive impairment and brain atrophy induced by transient cerebral ischemia in diabetic mice, independently of blood glucose lowering effect. This cerebroprotective effect of linagliptin was associated with the suppression of blood brain barrier disruption and the attenuation of cerebral oxidative stress. Thus, our present work highlights DPP-4 inhibition as a promising therapeutic strategy for cognitive impairment and cerebral vascular complications in type 2 diabetes.
Source: Cardiovascular Diabetology - Category: Cardiology Authors: MingJie MaYu HasegawaNobutaka KoibuchiKensuke ToyamaKen UekawaTakashi NakagawaBowen LinShokei Kim-Mitsuyama Source Type: research
More News: Brain | Cardiology | Cardiovascular | Diabetes | Diabetes Type 2 | Eating Disorders & Weight Management | Endocrinology | Heart | Neurology | Obesity | Study